ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Caco-2ϸ°ûÖêÊÇÈ˽᳦ÏÙ°©ÉÏÆ¤Ï¸°û£¬¿ÉÒÔ×ÔÐзֽâΪÀàËÆÈ˳ÉÊìµÄС³¦ÉÏÆ¤Ï¸°ûµ¥²ã¡£¾ÓÉÑо¿·¢Ã÷Caco-2ϸ°û»¹Äܱí´ï°üÀ¨ÌÇ£¬°±»ùËᣬµ¨ÖËáÒÔ¼°P¡ªgpºÍMRPsµÈתÔËÔØÌ壬Òò´ËCaco-2ϸ°ûÒѾ³ÉΪÑо¿Ò©Îï±»¶¯¼°×Ô¶¯×ªÔËÎüÊÕµÄÄ£×Ó¡£
£¨1£©Ñª½¬ÂѰ×Á¬ÏµÊÔÑ飨PPB£©£ºÆ¾Ö¤ 2014 °æ¡¶ÁÙ´²Ç°Ò©´ú¶¯Á¦Ñ§Ñо¿Ö¸µ¼ÔÔò¡·£¬ÊÔÑéÐèÉè¼Æ N=3£¬²¢¹Ø×¢Å¨¶ÈÒÀÀµÐÔºÍÖÖÊô²î±ð£»
£¨2£©ÌåÍâ´úлÑо¿£¨Metabolic Stability/MetID£©£ºÖØµã¹Ø×¢ÖÖÊô²î±ð£¬ÎªÌåÄÚ PK Ñо¿¡¢¶¾ÀíѧÆÀ¼Û¼°ÖÖÊôÑ¡ÔñÌṩ²Î¿¼£»
£¨3£©ÌåÍâÒ©ÎïÏ໥×÷Óã¨DDI£©Ñо¿£º°üÀ¨ P450 ÒÖÖÆÓëÓÕµ¼£¨Êý¾ÝÆÊÎö¿É²Î¿¼ FDA Ö¸ÄÏ£ºDDI 2006 Draft ºÍ 2020 In Vitro DDI£©£¬ÒÔ¼°Ã¸±íÐÍ£¨CYP/Non-CYP ´úл;¾¶£©Åжϣ»
£¨4£©×ªÔËÌåÑо¿£¨Transporter Substrate Assessment & Inhibition£©£ºÖ÷ҪתÔËÌå°üÀ¨ Caco-2¡¢P-gp¡¢BCRP¡¢OATP1B1¡¢OATP1B3¡¢OAT1¡¢OAT3 ºÍ OCT2¡£
£¨1£©·Ç·¿ÊÒÄ£×Ó£¨Noncompartmental Analysis, NCA£©£ºÒªÁì½ÏΪÇáÓ¯¿Í¹Û£¬Ëù»ñµÃµÄ²ÎÊý£¨t1/2¡¢Vd¡¢CL¡¢Cmax¡¢Tmax¡¢MRT¡¢AUC0¨Ct¡¢AUC0¨C¡Þ µÈ£©¿ÉÖª×ã IND É걨ҪÇ󣬵«²»¿ÉÓÃÓÚÕ¹ÍûºÍÄ£Ä⣬ÇÒ»ùÓÚÏßÐÔ PK ¼ÙÉè;
£¨2£©¾µä·¿ÊÒÄ£×Ó£¨Traditional Compartmental PK Model£©£ºÒªÁìÏà¶Ô¼òÆÓÒ×ÐУ¬¿ÉÄâºÏ·ÇÏßÐÔ PK Êý¾Ý£¬¿ÉÓÃÓÚÕ¹ÍûºÍÄ£Ä⣬²¢ÓÐÖúÓÚÊÔÑéÉ裻
£¨3£©ÈºÌåÒ©´úÄ£×Ó£¨Population PK Model£©£ºÔÚÁÙ´²Ç°½×¶ÎʹÓÃÏà¶Ô½ÏÉÙ£¬¸üÊʺϴ¦Öóͷ£Ï£º±Êý¾ÝºÍ¾ÙÐÐбäÁ¿ÆÊÎö£¨Èç NONMEM¡¢Monolix£©¡£
£¨1£©ÓµÓÐÁè¼Ý20ÄêµÄÊÖÒÕÓëÏîÄ¿ÂÄÀú£»
£¨2£©Ã¿ÄêÍê³ÉÔ¼20¸öÐÂÒ©µÄÁÙ´²Ç°DMPKÉ걨Ñо¿£»
£¨3£©Ã¿Äê´óÓÚ2000¸ö»¯ºÏÎïµÄÌåÄÚPKɸѡ£»
£¨4£©ÌṩPK/PDһվʽЧÀÍ£»
£¨5£©¾ß±¸¿¹Ìå¼°ADCµÄÁÙ´²Ç°DMPKÑо¿ÄÜÁ¦£»
£¨6£©ÓµÓÐÍ¬Î»ËØÒ©´úÑо¿µÄרҵÊÖÒÕÆ½Ì¨¡£